- Stocks
- Pharma & Healthcare
- Jagsonpal Ser
Jagsonpal Ser share price
NSE: JAGSNPHARMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Jagsonpal Ser at a glance
Jagsonpal Ser (NSE: JAGSNPHARM) closed at ₹211.40 on 22 Oct 2026, down 3.25% on the day. With a market capitalisation of ₹1,392 Cr, it ranks 1295th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 33.4× trailing earnings, against a return on equity of −4.4% in FY25. Over the past year the share price has fallen 0.2%. Its 52-week range is ₹155.00 (22 Jan 2026) to ₹264.50 (30 Jun 2026); the last close is 20.1% below the high. Promoters held 69.05% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,392 CrRank 1295 on NSE
- P/E (trailing)
- 33.4×
- Price to book
- 5.45×FY25
- ROE
- −4.4%FY25
- ROCE
- −8.3%FY25
- Debt to equity
- 0FY25
- Net profit margin
- −47,500.0%FY25
- Book value / share
- ₹8.86FY25
- 52-week high
- ₹264.5030 Jun 2026
- 52-week low
- ₹155.0022 Jan 2026
- 1-year return
- −0.2%
- RSI (14-day)
- 33.4
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −3.25% | −6.2% | −7.2% | −3.8% | −0.2% |
Jagsonpal Ser financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | −₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
| Operating profit | −₹1 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr | −₹1 Cr |
| Net profit | −₹1 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr | −₹1 Cr |
| EPS (₹) | −₹1.19 | ₹0.02 | −₹0.09 | −₹0.12 | ₹0.65 | −₹0.39 |
| Cash from operations | −₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | ₹1 Cr | −₹1 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹16 Cr |
Jagsonpal Ser shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 9 Jun 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 67.65% | 67.54% | 67.39% | 67.89% | 69.36% | 69.05% |
| Foreign institutions | 2.18% | 2.12% | 2.12% | 2.44% | 2.46% | 2.30% |
| Domestic institutions | 0.05% | 0.09% | 0.15% | 0.22% | 0.31% | 0.62% |
| Non-institutions | 30.12% | 30.25% | 30.34% | 29.45% | 27.87% | 28.03% |
Jagsonpal Ser vs peers
The listed Pharma & Healthcare companies nearest to Jagsonpal Ser by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SURAKSHASuraksha Diagnostic | ₹289.60 | +0.21% | −0.4% | ₹1,508 Cr | 46.9 | — |
| ASTECAstec LifeSciences | ₹666.40 | +1.28% | −10.0% | ₹1,485 Cr | — | — |
| AMRUTANJANAmrutanjan Health Care | ₹499.00 | +1.01% | −28.7% | ₹1,443 Cr | 24.9 | — |
| GKSLGujarat Kidney And Super Speciality | ₹179.49 | −1.40% | — | ₹1,415 Cr | 72.1 | — |
| TTKHLTCARETTK Healthcare | ₹989.70 | +2.77% | −12.0% | ₹1,398 Cr | 21.3 | — |
| JAGSNPHARMJagsonpal Ser | ₹211.40 | −3.25% | −0.2% | ₹1,392 Cr | 33.4 | — |
| FERMENTAFermenta Biotech | ₹455.25 | −3.14% | — | ₹1,340 Cr | — | — |
Ask anything about Jagsonpal Ser
Pivot answers on the live chart with evidence you can check, and tests strategies against JAGSNPHARM's own history. Try: “Why has JAGSNPHARM moved over the last three months?” · “Backtest a 50-day moving-average crossover on JAGSNPHARM over five years” · “Compare JAGSNPHARM with SURAKSHA on margins and valuation”
Frequently asked questions about Jagsonpal Ser
What is the share price of Jagsonpal Ser today?
Jagsonpal Ser (NSE: JAGSNPHARM) last closed at ₹211.40 on 22 Oct 2026. Its 52-week high is ₹264.50 and its 52-week low is ₹155.00.
What is the market cap of Jagsonpal Ser?
Jagsonpal Ser's market capitalisation is ₹1,392 Cr (₹1,392 Cr) at the 22 Oct 2026 close, ranking 1295th among the NSE companies Pivot tracks.
What is the P/E ratio of Jagsonpal Ser?
Jagsonpal Ser trades at a trailing P/E of 33.4. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 46.9.
What is the ROE and ROCE of Jagsonpal Ser?
Return on equity was −4.4% in FY25 and return on capital employed was −8.3% in FY25 (standalone figures).
Is Jagsonpal Ser a debt-free company?
Jagsonpal Ser is close to debt-free: its debt-to-equity ratio was 0 in FY25.
How has Jagsonpal Ser stock performed over the last year?
Jagsonpal Ser's share price has fallen 0.2% over the past year, −3.8% over three months and −7.2% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Jagsonpal Ser?
As of 30 Jun 2026: promoters 69.05%, foreign institutions 2.30%, domestic institutions 0.62%, non-institutions 28.03%.
Who are Jagsonpal Ser's competitors?
The listed Pharma & Healthcare companies closest to Jagsonpal Ser by market cap are Suraksha Diagnostic, Astec LifeSciences, Amrutanjan Health Care, Gujarat Kidney And Super Speciality, TTK Healthcare and Fermenta Biotech.
Is Jagsonpal Ser a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Jagsonpal Ser's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on JAGSNPHARM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with J · all NSE stocks · this page as text